Fresenius Kabi has recalled two lots of its chemotherapy drug fluorouracil after glass particulate was discovered in five vials.
The affected lots, No. 6120341 and No. 6120420, were distributed between Dec. 6, 2018, and Feb. 20, 2019.
"Products containing glass particulate should not be administered intravenously due to the potential for life-threatening consequences," the drugmaker said in its recall notice.
To date, Fresenius said it hasn't received reports of adverse events related to the glass particles.